All posts by imreal

HearingLife Brings New Cutting-Edge Hearing Technology to its Centers Nationwide


“HearingLife is proud to expand its product selection this World Hearing Day to ensure every customer has the chance to receive the personalized care they deserve and the devices to meet their unique hearing needs.”

Just in time for World Hearing Day, HearingLife, a leader in delivering life-changing, personalized hearing care, announces the availability of Oticon Real™, the newest top-of-the-line hearing product from Oticon.

Oticon Real™ are the new group of premium hearing care products designed with BrainHearing™ technology to support the brain’s natural hearing capabilities, which gives users access to full sound scenes, further improving quality of life. These real-life benefits are unlike any other aid on the market and provide a richer sound experience that does not compromise speech clarity.

The Oticon Real™ hearing aids have responded to hearing aid wearers’ biggest complaints with these cutting-edge benefits:


  • Includes a “Deep Neural Network (DNN)” with over 12 million real-life sounds programmed in to allow users to hear each sound with detail and clarity
  • The Wind and Handling Stabilizer increases speech clarity in windy situations¹
  • Distracting handling noises, such as contact with glasses or hair rubbing on the earpiece, are minimized
  • Soft and loud sudden sounds² are instantly and precisely balanced

Hearing is as unique as a fingerprint. “World Hearing Day reminds us of the importance of accessible hearing care that starts with an assessment from a licensed hearing care provider to determine the best course of action for each individual,” say HearingLife President, Dean Pappous. “HearingLife is proud to expand its product selection this World Hearing Day to ensure every customer has the chance to receive the personalized care they deserve and the devices to meet their unique hearing needs.”

Oticon Real™ is available in four styles, nine colors, and three performance levels. One can also seamlessly connect to the Oticon Companion app for additional capabilities, such as wireless headset functions and streaming someone’s voice with Oticon’s ConnectClip remote microphone.

“Almost 30M adults in the US could benefit from some type of hearing aid, yet the devices are still widely stigmatized and hearing loss is a prevalent problem,” adds Dr. Leslie Soiles, Chief Audiologist for HearingLife. “As someone with hearing loss who uses hearing aids, I am personally so impressed by the clarity Oticon Real provides. Additionally, they effectively manage competing background noise so I can now fully enjoy social gatherings.”

Consumers can experience the benefits of Oticon Real firsthand by scheduling their appointment (https://www.hearinglife.com/book-appointment/online-booking) with HearingLife and receiving a complimentary hearing assessment* with a trained hearing care professional. The assessment includes an opportunity to demo the devices in the office. HearingLife offers a risk-free hearing aid trial** for 30 days. This program enables the devices to be purchased, professionally fit, and customized for the individual’s unique hearing needs. Customers will receive personalized counseling and adjustments to acclimate to the devices during the trial period. If unsatisfied, the devices can be returned for a full refund within the trial period.

About HearingLife

HearingLife is a national hearing care company and part of the Demant Group, a global leader in hearing healthcare built on a heritage of care, health, and innovation since 1904. HearingLife operates nearly 700 hearing care centers across 42 states. We follow a scientific, results-oriented approach to hearing healthcare that is provided by highly skilled and caring professionals. Our vision is to help more people hear better through life-changing hearing health delivered by the best personalized care. To learn more, visit: https://www.hearinglife.com.

PRESS CONTACT:

Kaplow Communications

(646) 747-3551

hearinglife@kaplow.com

¹Gade et al. (2023) Wind & Handling Stabilizer – Evidence and user benefits. Oticon Whitepaper;

²Santurette et al. (2023). SuddenSound Stabilizer – Evidence and user benefits. Oticon Whitepaper

*The purpose of this hearing assessment and/or demonstration is for hearing wellness and to determine if the consumer may benefit from using hearing aids, which may include selling and fitting hearing aids. Products demonstrated may differ from products sold. Assessment conclusion is not a medical diagnosis and further testing may be required to diagnose hearing loss. The use of any hearing aid may not fully restore normal hearing and does not prevent future hearing loss. Hearing instruments may not meet the needs of all hearing-impaired individuals.

**30-Day Risk-Free Trial begins at the date of purchase. If you are not completely satisfied, you can return it within 30 days for a full refund or exchange, varies by state. Hearing aid must be returned in the same condition as received, ordinary wear and tear excluded. See office for complete details and restrictions. Other exclusions may apply. This offer is available at most HearingLife offices. Check with your local provider.

Share article on social media or email:

Prevent Blindness to Hold Eighteenth Annual “Eyes on Capitol Hill” Advocacy Event


Prevent Blindness to hold 18th Annual Eyes on Capitol Hill patient advocacy event.

“Now in our 18th consecutive year, we are proud to continue this legacy of patient advocacy and look forward to working with government officials to help save sight,” said Jeff Todd, president and CEO of Prevent Blindness.

Prevent Blindness, the nation’s leading nonprofit eye health and safety group, will be holding its eighteenth annual Eyes on Capitol Hill advocacy event on March 7-8, 2023. Entering its 115th year as a public health advocacy organization, Prevent Blindness once again will bring together patients, care partners, allied personnel, and medical professionals to speak directly with their elected officials to discuss a variety of vision and eye health issues, and the need for legislative and funding support.

Issues such as inequitable access to eyecare, health and income disparities, the negative impact of vision loss on independence and mental health, and the emotional and financial toll that eye diseases and conditions continue to impart, are just a few of the topics that Prevent Blindness continues to raise awareness and provide education on.

Eyes on Capitol Hill also provides an opportunity for participants of the Prevent Blindness ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program to share their stories with legislators and utilize other essential advocacy communication skills learned throughout the duration of their experience in the program. Prevent Blindness is pleased to welcome 34 new ASPECT-trained advocates and 22 returning ASPECT graduates to this year’s event. In addition, this is also the first year in which trainees of the new Eyes on Capitol Hill Team Leader Training Program will lead groups of advocates in meetings with Members of Congress. To prepare them for their leadership roles, Team Leaders go through extensive training to learn about the federal budget and appropriations process, the basics of public health, and how to coach advocates to improve their advocacy skills.

2023 Eyes on Capitol Hill advocates will specifically ask elected officials to:


  •     support a funding level of $5 million in Fiscal Year 2024 for the Vision and Eye Health Budget Line, which provides federal funding for the Centers for Disease Control and Prevention’s (CDC) Vision Health Initiative. The CDC’s Vision Health Initiative (VHI) conducts national-level surveillance, engages in partnerships that promote early detection and connect people at high risk for eye diseases to eye care, and shares best practices with states and communities about incorporating vision and eye health into community-level interventions.
  •     maintain the current funding level of the CDC’s glaucoma program at $4 million in FY2024. This funding will allow the CDC to continue glaucoma detection, referral, and treatment programs through community-level partnerships that have successfully reached high-risk and underserved populations and connected them to glaucoma care.
  •     join the bipartisan, bicameral Congressional Vision Caucus (CVC), dedicated to strengthening and stimulating a national dialogue and policy on vision-related problems and disabilities. The mission of the CVC is to raise awareness about the increasing number of Americans at risk for age-related eye diseases and those who face vision loss due to chronic disease.

“The Eyes on Capitol Hill program provides our legislators a unique opportunity to truly understand how vision issues impact their constituents through the personal stories of patients, families, medical professionals and more,” said Jeff Todd, president and CEO of Prevent Blindness. “Now in our 18th consecutive year, we are proud to continue this legacy of patient advocacy and look forward to working with government officials to help save sight.”

For more information on Eyes on Capitol Hill, or Prevent Blindness and its advocacy initiatives, please visit PreventBlindness.org/advocacy-initiatives/.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Share article on social media or email:

Mediliant Group Announces New President of Their Facility in Plymouth, Indiana


News Image

In a continued effort to respond to customer needs and further boost company momentum, leaders in medical device contract manufacturing, Mediliant Group, has appointed industry expert Jason Ratcliffe as the new President of the organization’s CTE facility in Plymouth, Indiana.

Mr. Ratcliffe has an extensive career in the manufacturing industry, working in several key positions of increasing responsibility in the automotive, defense, and medical device industries. Based in Detroit, Michigan, Jason’s career began in the automotive industry where he spent a decade in various roles from production management, and engineering before specializing in lean manufacturing. From here, Jason moved to Beaver Aerospace & Defense where he was the General Manager of multiple sites. Jason’s success at Beaver was a springboard into the medical device industry where he enjoyed a period of huge success as the GM of Orchid’s flagship facility, Bridgeport as well as two smaller sites, ultimately responsible for over $150m of revenue and 700 plus employees. Jason’s experience extends into procurement and sourcing, international business leadership, and people development. In his spare time, he is an owner in his church, an attentive husband and father, and an active DJ.

“We are delighted to have Jason join our team and lead our operational efforts at CTE. He is a result-orientated leader who facilitates strong, high-performing teams that have an extremely customer-focused mindset. We expect Jason to build on the excellent reputation of CTE and the strong foundations the current leadership team provides there, to deliver our strategy to become a top-tier Spine, Trauma, & Extremities contract manufacturer.” - Matt Burba, Mediliant Group CEO.

Jason’s expertise, considerable leadership and management skills, and ability to work in a high-pressure environment make him the ideal person to take Mediliant Group’s CTE facility to the next level. As the company continues to build momentum, expand capabilities, and enhance customer experiences, the growth of the leadership team plays an important role in the overall success.

For more information on Mr. Ratcliffe and the continued growth of the Mediliant Group, visit mediliant.com.

Share article on social media or email:

The Global Wellness Summit, Heading to Fast-Transforming Qatar in 2023, Announces Host Sponsor and Co-Chairs


This 17th Summit is of great significance as it aims to positively impact the wellness of our people and communities and highlight Qatar’s leading position in the future of global health and wellness

The Global Wellness Summit (GWS), the leading conference for the $4.4 trillion business of wellness, today announced the host sponsor and co-chairs for its 17th annual event that will take place in Doha, Qatar from November 6-9. Qatar, one of the smallest but mightiest Middle Eastern countries, where cultural authenticity meets hyper-modernity—and the sea meets the desert—is a powerful location for the conference. With its Qatar National Vision 2030, the country is at a pivotal time in its history, with an extraordinary mission and investment plan to become a global leader in sustainability, health and wellness, tourism, sports and culture. With its recent, successful hosting of the FIFA World Cup, $220 billion was spent radically reimagining its infrastructure, with 150 new hotels and resorts, and new smart, sustainable cities, museums, public beaches and green space, subway systems and sports complexes.

Today, executives from the GWS and Msheireb Properties held a press event in Doha, introducing Qatari media to what hosting the world’s most prestigious conference on the business of wellness will mean for the country.

Host Sponsor, Msheireb Properties—Qatar’s Sustainability and Wellness Powerhouse:

The 2023 host sponsor, Msheireb Properties, is a subsidiary of Qatar Foundation for Education, Sciences and Community Development and Qatar’s leading sustainable property developer, supporting the goals of Qatar’s 2030 Vision and Qatar Foundation’s objectives. Its mission is to change the way people think about urban living and to improve their overall quality of life, through innovations that encourage social interaction, respect for culture, and greater care for the environment. Its signature project, Msheireb Downtown Doha, is one of the smartest, most sustainable city districts, which employs a new approach to urban planning by combining traditional methods and modern technology aimed at preserving the environment as well as the cultural identity of Qatar. All buildings are either Gold or Platinum LEED-certified.

The company also developed Zulal Wellness Resort, the Middle East’s first full-immersion wellbeing resort, which offers unique services and treatments based upon Islamic healing principles and using indigenous ingredients. Just an hour from Doha on a private coastal location, GWS delegates will be able to experience Zulal pre- or post-conference.

“We are honored to host the 2023 Global Wellness Summit in Qatar at our smart and sustainable city Msheireb Downtown Doha,” said Eng. Ali Al Kuwari, Msheireb Properties’ CEO. “This 17th Summit is of great significance as it aims to positively impact the wellness of our people and communities and highlight Qatar’s leading position in the future of global health and wellness.”

The Co-Chairs:

Each year, the Summit brings together high-profile global executives from health and wellness companies, doctors, investors, academics and technologists to immerse the hundreds of invite-only delegates (from 40+ nations) in three days of keynotes and panels on what’s ahead for the business of wellness. The co-chairs that will shape this year’s agenda are:

Eng Ali Al Kuwari is the CEO of Msheireb Properties, where he will lead the development and implementation of the strategic and operational plans of Msheireb Properties and Msheireb Downtown Doha (MDD), to enhance its position as a leading tourist and business destination for work and living. With 22 years of experience, Al Kuwari is one of the prominent Qatari talents and the leading engineers of Msheireb Downtown Doha since its inception. He also led the execution and operations of major facilities at MDD including Mandarin Oriental, Al-Wadi Hotel M Gallery and Park Hyatt, in addition to Zulal Wellness Resort. During the recent World Cup FIFA Qatar 2022, he supervised the relevant event operations in MDD. He holds a Bachelor of Science in industrial engineering from the University of Miami and an Executive MBA from HEC Paris in Qatar.

Cathy Feliciano-Chon is founder and managing director of CatchOn – A Finn Partners Company, one of Asia’s leading brand communication consultancies in hospitality, travel, wellness, food and design, with offices in Hong Kong and Shanghai. She is also a GWS Advisory Board member. A marketing communications expert, Feliciano-Chon has a long track record in transforming, building and creating brands, and is renowned for her keen insights on the Asian consumer and emerging trends. Feliciano-Chon was included in Tatler Asia’s “Most Influential List 2021.” She is widely published and quoted in major publications, and is a sought-after speaker at international conferences.

“It’s an honor to co-chair this year’s Summit in Qatar at such a transformative time in the country’s history. In a relatively short time, Qatar has become a formidable tourism destination and an exciting cultural hub underpinned by a deep commitment to sustainable development,” said Feliciano-Chon. “The annual Global Wellness Summit brings these varied industries and sectors together to address the critical issues of our time.”

More About Qatar and Its Sustainability, Wellness and Tourism Vision:

Qatar has a unique landscape, with its 350-mile-long coastline of beaches and vast Khor Al Udeid Desert—and coastal Doha is known for its spectacular ultramodern architecture inspired by ancient Islamic design. It has the highest GDP per capita—and is the safest country—in the world. With its long-term focus on sustainable development and tourism, it has undergone a profound recent reimagining, with a flurry of major infrastructure, hospitality and cultural projects—–whether the impressive Education City, home to satellite campuses of famous international universities; or M7, a center for innovation in design, fashion and tech; or new museums, such as the high-tech Olympic and Sports Museum.

Wellness and medicine are at the heart of the country’s development vision—from the new, state-of-the-art The View Hospital, a satellite of the famous Cedars-Sinai Medical Center, to so many new world-class spa resorts (such as the new Mandarin Oriental, the brand’s first property in the Middle East), to Zulal Wellness Resort, a natural healing wellness destination. Attracting more major sporting events is also key to the country’s tourism plan and global brand, with PwC recently reporting that Qatar is “well-positioned” in the sporting event management space. Following the World Cup, more mega events are ahead (from the 2023 AFC Asian Cup to the 2030 Asian Games) and the country is also expected to bid on the 2036 Olympics. New intersections between wellness and sports will be a topic at the 2023 GWS. Already one of the fastest-growing hospitality markets, Qatar’s aim is to become one of the world’s leading tourism destinations, attracting six million visitors by 2030. As global travel analyst Skift recently summarized: “Qatar is, more so than many other tourism stories today, a fascinating mix of vision, ambition and taste.”

Registration for the 2023 Summit is now open. Apply here.

About the Global Wellness Summit: The Global Wellness Summit is an organization that brings together leaders and visionaries to positively shape the future of the $4.4 trillion global wellness economy. In addition to an annual conference, held at a different location around the globe, GWS also hosts regular virtual gatherings, including Wellness Master Classes and collaborative Wellness Sector Spotlights. Each year, it holds an in-person Wellness Real Estate & Communities Symposium. The organization’s annual Global Wellness Trends Report offers expert-based predictions on the future of wellness that are oft-quoted in the media. The 17th annual GWS will be held in Qatar from November 6-9, 2023.

Leading Patient Safety Solution, MedSitter, Appoints Holly Miller as President


News Image

MedSitter, a leading remote patient observation solution, announced the appointment of Holly Miller as President. Miller comes to MedSitter with a proven track record of success in the healthcare technology industry. She will oversee the company’s strategic direction, focusing on driving growth through service expansion.

Miller has led revenue growth within the acute and post-acute SaaS space for over 20 years. Miller’s previous experience includes HealthStream and, most recently, as Chief Revenue Officer at PlayMaker, a successful acquisition by Trella Health, Cressey, and Co.

“Initially, I was drawn to MedSitter’s mission,” says Miller, “I believe this service can go a long way towards keeping patients safe across the care continuum. MedSitter represents a leap forward in the care delivery model, and I am thrilled to be working with such a dedicated and passionate group of people. Together, we plan to transform the way patient safety is handled.”

Miller will first focus on the overall go-to-market strategy of MedSitter to expand our service to existing customers and new clients. Ultimately, the goal is establishing MedSitter as the standard of care for patient observation.

“We are so excited to welcome Holly to the MedSitter team,” says Tracy Mills, CEO. “Her addition is vital to our aggressive growth plan, and her track record of successful leadership will prove to be a tremendous asset.”

To learn more about MedSitter, visit us online at http://www.MedSitter.com

About MedSitter

MedSitter helps overburdened clinicians to remotely observe patients to meaningfully improve patient safety and satisfaction without straining staff resources. The remote patient observation system is being leveraged by top healthcare systems across the nation with fantastic results. From the first call all the way through account maturity, MedSitter provides exemplary customer support which helps clinicians to proactively meet patient needs. To learn more about MedSitter and the innovative patient safety program it supports, visit http://www.medsitter.com.

For Press Inquiries:

Kate Pascucci

Vice President Marketing

Kate.pascucci@teamids.com

Share article on social media or email:

Codoxo Recognized as One of the Southeast Region’s Fastest Growing Private Companies by Inc. Magazine


Codoxo

Our innovative and secure healthcare AI solutions are driving substantial savings across the ecosystem to ensure they stay affordable and effective.

Codoxo, a trusted provider of healthcare artificial intelligence solutions for healthcare payers, agencies and pharmacy benefits managers (PBMs), today announced that it has been named No. 20 on the Inc. 5000 Regionals Southeast list based on its significant two-year growth rate. The Inc. 5000 Southeast list ranks the fastest-growing private companies based in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, Puerto Rico, South Carolina, and Tennessee. Of the 200 companies that made the Southeast list, Codoxo is the seventh-fastest growing company in Georgia and the second-fastest growing in the “Health Services” category.

“Being recognized as one of the fastest growing companies in the Southeast, especially considering the challenges and impact of the pandemic on healthcare, is an outstanding tribute to the amazing work of our team and their collaboration with our clients,” stated Dr. Musheer Ahmed, CEO and Founder of Codoxo. “We are sharply focused on advancing the industry to address the rampant fraud, waste and abuse that contributes to skyrocketing healthcare costs. Our innovative and secure healthcare AI solutions are driving substantial savings across the ecosystem to ensure they stay affordable and effective.”

Codoxo has earned several awards and accolades that further underscore the company’s upward trajectory within the growing healthcare cost containment industry. Just this month, the company was recognized as a 2023 Technology Association of Georgia (TAG) Technology Awards Finalist. Additionally, Codoxo was awarded the 2022 Fierce Healthcare Innovation Award in the Data Analytics/Business Intelligence category and was also recognized by Aite Group in the “Aite Matrix: Payment Integrity in Healthcare” Report as a “mighty player,” with “AI prowess” as an industry differentiator, among several others.

“This year’s Inc. 5000 Regional winners represent one of the most exceptional and exciting lists of America’s off-the-charts growth companies. They’re disruptors and job creators, and all delivered an outsize impact on the economy. Remember their names and follow their lead. These are the companies you’ll be hearing about for years to come,” said Scott Omelianuk, editor-in-chief of Inc.magazine.

In the healthcare industry, fraud, waste and abuse is a multi-billion-dollar problem, accounting for as much as 10% of the $3.8 trillion spent on healthcare each year. It has commanded the attention of healthcare executives who want money-saving solutions driven by AI, like that from Codoxo, to help identify and reduce risk and contain healthcare costs.

About Codoxo

With a mission to make healthcare more affordable and effective for everyone, Codoxo is the premier provider of artificial intelligence-driven solutions and services that help healthcare companies and agencies proactively detect and reduce risks from fraud, waste, and abuse and ensure payment integrity. The Codoxo Unified Cost Containment Platform helps clients manage costs across network management, clinical care, provider coding and billing, payment integrity, and special investigation units. Our software-as-a service applications are built on our proven Forensic AI Engine, which uses patented AI-based technology to identify problems and suspicious behavior far faster and earlier than traditional techniques. Codoxo is a Fierce Healthcare Innovation Award winner and has been recognized by the Inc. 5000 Regionals list for growth. Our solutions are HIPAA-compliant and operate in a HITRUST-certified environment. For additional information, visit http://www.codoxo.com.

More about Inc. and the Inc. 5000 Regionals

Methodology

The 2023 Inc. 5000 Regionals are ranked according to percentage revenue growth when comparing 2019 and 2021. To qualify, companies must have been founded and generating revenue by March 31, 2019. They had to be U.S.-based, privately held, for-profit, an independent—not subsidiaries or divisions of other companies—as of December 31, 2021.(Since then, a number of companies on the list have gone public or been acquired.) The Minimum revenue required for 2019 is $100,000; the minimum for 2021 is $1 million. As always,Inc. reserves the right to decline applicants for subjective reasons.  

About Inc. Media 

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools,connections, and community to build great companies. Its award-winning multi platform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers and the credibility that helps them drive sales and recruit talent.

The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit http://www.inc.com. 

Share article on social media or email:

PathGroup Chooses Proscia To Deliver Next Generation Of Cancer Diagnosis For Millions of Patients


“We are thrilled that Proscia shares our vision for a fully digital future,” said Ben W. Davis, MD, CEO of PathGroup.

Proscia®, a leading provider of digital and computational pathology solutions, today announced that PathGroup, one of the largest providers of anatomic, clinical, digital, and molecular pathology services in the United States, will advance the 150-year-old standard of diagnosis for diseases like cancer with Concentriq® Dx. PathGroup is expanding its operations with Proscia’s software platform to further enhance the delivery of fast, high quality results for millions of patients, helping to better inform treatment decisions.

Up to 70% of clinical decisions depend on pathology.[1] Digital pathology shifts diagnosis from microscope to whole slide image, unlocking insights previously unseen by the human eye to realize the promise of precision medicine. It also drives powerful efficiency gains that are helping laboratories to overcome a range of systemic challenges; the number of cancer cases is expected to rise 47% between 2020 and 2040[2] while only 65% of pathology groups looking to hire could fill all open roles in 2021[3].

“Taking this next step on our journey requires a company to serve as our trusted partner and a platform that will grow across our network,” said Ben W. Davis, MD, CEO of PathGroup. “After a robust evaluation, we are thrilled that Proscia shares our vision for a fully digital future and confident that Concentriq Dx will enable us to rapidly expand upon our existing digital pathology foundation. With Proscia’s nimbleness and speed to innovation, we will leverage the latest technology, including AI, to provide the next generation of diagnosis for millions of patients.”

Concentriq Dx* is a modern pathology platform that drives routine diagnosis for laboratory networks of all sizes. By streamlining collaboration and enabling remote image viewing, it empowers pathologists to deliver higher quality results through broadened access to expertise. The platform also offers world-class interoperability with leading scanners and image analysis applications and is designed for realizing the promise of pathology’s AI-powered future to meet evolving needs.

“PathGroup’s transition to Concentriq Dx is a testament to the platform’s ability to deliver on the full promise of digital pathology at scale,” said David West, Proscia’s CEO. “Pathology data is one of healthcare’s most valuable assets, and PathGroup is now well-positioned to fully capitalize on its potential to transform patient care.”

One of the largest comprehensive pathology services providers, PathGroup currently supports more than 15,000 referring physicians and over 200 hospital customers with diversified laboratory testing services and high-touch customer service. Its team of more than 225 pathologists represents every pathology subspecialty. PathGroup operates a fully digital primary diagnosis approach at its centralized laboratory in Nashville, Tennessee.

“Digital pathology is quickly becoming synonymous with pathology,” said Steve Holloway, Company Director at Signify Research. “As leading laboratories like PathGroup grow their implementations, they continue to set a new standard of diagnosis.”

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

About PathGroup

Founded in 1965, PathGroup is a premier provider of anatomic, clinical, molecular, and digital pathology services in the United States. Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers, and most importantly, patients. One Lab; Total Service. For more information, visit pathgroup.com.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.

[1] NHS England (2017). Digital First: Clinical Transformation Through Pathology Innovation. National Pathology Programme; doi: https://www.england.nhs.uk/wp-content/uploads/2014/02/pathol-dig-first.pdf

[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

[3] Gross, D. et al (2022). Strong Job Market for Pathologists: Results From the 2021 College of American Pathologists Practice Leader Survey. Arch Pathol Lab Med 2022; doi: https://doi.org/10.5858/arpa.2022-0023-CP

Share article on social media or email:

Highmark Health, Allegheny Health Network Unveil North Fayette Health + Wellness Pavilion


News Image

“This investment in Pittsburgh’s western suburbs is an exciting expansion of our footprint, and we look forward to the remarkable health experiences that it will provide to those who seek care here,” said Bruce Meyer, MD, Executive Vice President and Western PA Market President, Highmark Health.

Representatives of Highmark Health and Allegheny Health Network (AHN) today joined community leaders for a ceremonial ribbon-cutting to celebrate the launch of AHN’s North Fayette Health + Wellness Pavilion – a state-of-the-art facility offering an array of primary and specialty outpatient services anchored by the network’s Center for Reproductive Medicine.

The new $70 million, 68,000-square-foot AHN facility, located at 200 Quinn Drive in North Fayette Township, will officially open to patients on Monday for most services being offered at the location. AHN’s Center for Reproductive Medicine will open to patients in May.

“Today marks the latest milestone for AHN and Highmark Health in our ongoing journey to transform health care for patients and their families in the communities where they live and work,” said Bruce Meyer, MD, Executive Vice President and Western PA Market President, Highmark Health. “This investment in Pittsburgh’s western suburbs is an exciting expansion of our footprint, and we truly look forward to the remarkable health experiences that it will provide to those who seek care here.”

AHN North Fayette will serve as the new home base for AHN’s comprehensive Center for Reproductive Medicine, a leading reproductive endocrinology program and licensed ambulatory surgery facility for infertility treatments. The AHN reproductive medicine team will work exclusively from the new location to provide tailored plans, from initial consultation through prescribed care journey, which could include ovulation-stimulating medications, in vitro fertilization (IVF), intrauterine insemination, and sperm testing, among other infertility therapies.

AHN worked closely with clinicians, architects and buildings designers to create a world-class facility centered around the patient experience. AHN North Fayette features a separate, distinct entrance for women undergoing infertility treatments. Inside, the center is equipped with private, spacious waiting areas and exam rooms – away from obstetric patients, families, and those who may be expecting.

“Thoughtful collaboration among our teams has resulted in a beautiful, patient-centered design that considers the deeply complex health journey of these patients, both physically and emotionally,” said Marcia Klein-Patel, MD, PhD, Chair of AHN Women’s Institute, “With their own entrance and separate facilities, women undergoing infertility procedures are welcomed in an appropriate, calming environment and will be among those who are on similar care paths.”

The surgical center, post-op area and outpatient labs are also accessed via a designated entrance and exit. For patients accessing primary care or other specialty outpatient services, the facility’s main entrance will direct them to a centralized registration hub.

Additional clinical services offered at the Pavilion include primary care, behavioral health for adults and children, including AHN Women’s Behavioral Health; a full spectrum of diagnostic imaging capabilities; and onsite specialists in orthopedics, endocrinology, rheumatology, obstetrics and gynecology services; as well as physician-led rotating specialty clinics for maternal-fetal medicine, urogynecology, cardiology, gastroenterology, pulmonology, neurology and neurosurgery, pain medicine, bariatrics and podiatry.

Express care and walk-in services will also be available at the Pavilion for extended and weekend hours starting in May, complemented by an on-site laboratory and advanced imaging suite. AHN North Fayette will house one of the area’s first 3T MRI scanners – a leading-edge technology that produces exceptionally detailed images of the anatomy. CT, ultrasound, DEXA bone density scanner, Xray and mammography are also available at the Pavilion.

“The opening of this magnificent facility is yet another example of our Living Health model coming to life through more convenient community access to services, through innovative solutions and care pathways that help patients live their best lives and through leading clinical expertise across every discipline,” said Jim Benedict, chief operating officer at AHN.

AHN partnered with Orangestar Property Advisors and Sentinel Construction to develop the North Fayette Health + Wellness Pavilion. RM Creative served as the project architect.

North Fayette will become AHN’s sixth Health + Wellness Pavilion, joining others serving the communities of Wexford, Bethel Park, Peters Township and Erie’s east and west sides. Today’s ribbon-cutting comes on the heels of the opening of AHN’s Montour Sports Medicine complex in November 2022, AHN Seneca Valley outpatient center in August 2022, and AHN Wexford hospital in September 2021.

Link to facility images here.

About the Allegheny Health Network:

Allegheny Health Network (AHN.org) is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is composed of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, multiple employed physician organizations, home and community based health services, a research institute, and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes, autoimmune disease and more. AHN employs approximately 22,000 people, has more than 2,600 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

Flourish Medical CEO Presents at LSI Emerging MedTech Summit


Joanne Rupprecht, CEO of Flourish Medical, LLC, will present a novel women’s health medical device at this year’s LSI Emerging MedTech Summit

Joanne Rupprecht, CEO of Flourish Medical, will present a novel women’s health medical device at this year’s LSI Emerging MedTech Summit.

Flourish designs and manufactures a single-use disposable device that helps women manage stress urinary incontinence, a condition affecting more than 15 million women in the United States alone.

Joanne Rupprecht, CEO of Flourish Medical, LLC, will present a novel women’s health medical device at this year’s LSI Emerging MedTech Summit, taking place March 21-23 in Dana Point, California.

Flouish, dedicated to meeting the needs of the women’s health market, is the designer and manufacturer of a single-use disposable device that helps women manage stress urinary incontinence (SUI). Affecting more than 15 million women in the United States alone, stress incontinence is a condition that can affect women in many stages of life, and is the most common form of urinary incontinence.

At the summit, which connects medtech leaders with investors, Rupprecht will detail the SUI market, the lack of existing solutions for the SUI problem, and how Flourish is positioned to leverage current opportunities.

“In Flourish Medical, we have in place what we need to commercialize the device: an experienced team, a detailed plan, tremendous intellectual property and a clear path to regulatory approval,” says Rupprecht. The company is seeking $1.5 million in its seed round of funding, and $5 million in Series A funding upon FDA 510(k) clearance.

“The Flourish device means a positive lifestyle change for millions of women,” says Rupprecht. Research shows that fewer than 25% of women with incontinence seek medical advice or help for their problem, she explains, and that many of them are not candidates for surgery. Others simply prefer not to have surgery or an invasive procedure. “Flourish provides the chance for these women to easily manage this condition and engage in all the activities they wish to, without worry.”

Flourish Medical, LLC (http://www.flourish-medical.com)

Flourish Medical, LLC, is a medical device development and manufacturing company serving the needs of the women’s health market. The company’s flagship product, Flourish, is a novel, single-use, disposable device that helps women manage stress urinary incontinence. Flourish Medical is based in Boulder, Colorado.

Share article on social media or email:

Mount Sinai Expert Urge Colon Cancer Awareness and Education to Reverse Decline in Screening Rates during Pandemic


Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States. Although highly treatable and preventable, about 140,000 Americans are diagnosed and more than 50,000 people die each year, according to the Centers for Disease Control and Prevention (CDC). The United States Preventative Task Force recommends starting age of screening from 45 to 50.

More than 93% of colorectal cancer cases occur in people 45 years old or older. More than 75-90% of colorectal cancer cases can be avoided through early detection and removal of pre-cancerous polyps, and as many as 60% of colorectal cancer deaths could be prevented if men and women over the age of 45 were screened routinely.

In an effort to increase awareness and screening, Mount Sinai has expanded Colorectal Cancer Awareness Initiatives across all eight hospital sites during the month of March to provide patients with access to health professionals to discuss prevention, screening options, and risk factors. Mount Sinai experts will be available from various expertise to answer questions on diet, genetic counseling, the colonoscopy procedure and ways to schedule and support offered after diagnosis, and more.

Experts available for interview:

David Greenwald, MD, Director of Clinical Gastroenterology and Endoscopy at The Mount Sinai Hospital; Steven Itzkowitz, MD, Professor of Medicine and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and Chair of the National Colorectal Cancer Roundtable; Laura Manning, MPH, RD, CDN, Clinical Nutrition Coordinator in the Department of Gastroenterology at The Mount Sinai Hospital; and Randolph Steinhagen, MD, Professor of Colon & Rectal Surgery at The Mount Sinai Hospital

Prevention Tips:


  • Schedule a Screening: a colonoscopy is the preferred screening method as it allows for both detection and removal of precancerous polyps during the same procedure. Other screening options include a flexible sigmoidoscopy, CT colonography, and home-based stool tests including the fecal occult blood test (FOBT), fecal immunochemical test (FIT), and a combined fecal immunochemical test with DNA test (FIT-DNA test). Individuals should discuss all of these options with their doctor to find which method works best for their lifestyle.

Know Your Risk Factors:

  • Age – More than 90% of colorectal cancer cases occur in people 45 years old or older and death rate increases with age.
  • Family history – As many as 1 in 3 people who develop colorectal cancer have other family members who have been affected by this disease. The risk is even higher if a relative was diagnosed under age 50 or if more than one first-degree relative (parent, sibling, child) has been affected.
  • Racial and ethnic background – Colorectal cancer affects people of all races and ethnicities. However, colorectal cancer disproportionately affects the Black community, where the rates are the highest of any racial/ethnic group in the US. African Americans are 20% more likely to get colorectal cancer and about 40% more likely to die from colorectal cancer than most other groups. Colorectal cancer screening rates remain lowest among Black and Hispanic/Latino communities.
  • Lifestyle factors – Common lifestyle factors that may increase colorectal cancer risk include: obesity; cigarette smoking; lack of exercise; overconsumption of fat, red and processed meats; not eating enough fiber, fruits and vegetables; and drinking alcohol excessively.
  • Pre-existing health conditions – Inflammatory bowel diseases (IBD), such as ulcerative colitis or Crohn’s disease, and less common genetic syndromes, such as familial adenomatous polyposis (FAP) or Lynch syndrome, significantly increase the risk of developing colorectal cancer. These patients are recommended to start screening at a younger age and more frequently.

Warning Signs & Symptoms:

  • A change in bowel habits, such as diarrhea, constipation or narrowing of the stool, lasting for more than a few days
  • Rectal bleeding, dark stools or blood in the stool
  • Cramping or abdominal pain
  • Weakness and fatigue
  • Unintended weight loss

Colon Cancer Screen Events in March:

  • March 2nd – Mount Sinai Beth Israel- Linsky Lobby – 281 1st Ave., New York NY 10003
  • March 7th – Mount Sinai West – Main Lobby – 1000 Tenth Avenue, New York, NY 10019
  • March 9th – Mount Sinai Morningside – Ambulatory Care Center Lobby – 440 W 114th St., New York, NY 10025
  • March 14th – Ansonia – Primary Care Physicians – 2nd Floor Lobby – 2109 Broadway 2nd Floor, New York, NY 10023
  • March 16th – Mount Sinai Union Square – 2nd Floor – 10 Union Square, New York, NY 10003
  • March 21st – The Mount Sinai Hospital- Guggenheim Pavilion – 1468 Madison Ave, New York, NY 10029
  • March 28th – Upper West Side – Upstairs Lobby – 230 West 74th Street, New York, NY 10023
  • March 31st – Mount Sinai Brooklyn – Main Lobby – 3201 Kings Hwy Brooklyn, NY 11234

The Mount Sinai Health System

The Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, over 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email: